Researches and develops pharmaceuticals for rare diseases in haematology, immunology, and genetic/metabolic conditions. Now — the numbers.
This is an established company with proven profits.
Average growth of 16% a year over the last 4 years. Every year shown ended in profit.
The gap is $1.1B. In times of high interest rates, a gap like that can squeeze a company.
The market pays 339.5× for every dollar this company earns in a year — a price that already assumes things go well.
No analyst target is on record for this company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 4 years, sales grew about 16% a year on average.
The company’s market value is 339 times its annual profit. Even a small disappointment could hit the price hard.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.